The Secondary Education for Human Capital Competitiveness Project will support priorities of phase 2 of Cambodia's Secondary Education Blueprint 2030. The project's impact is aligned with the vision of the Ministry of Education, Youth, and Sport (MOEYS) and the government's strategy, which highlight the importance of high-quality human resources to develop a knowledge-based society.2 The outcome will be effectiveness of a gender-inclusive upper secondary education system improved.

This report emphasizes that open and fair trade is essential for Asia and the Pacific’s transition to low-carbon economies and outlines the important role of Aid for Trade in this transition.

Nobel prizewinning theoretical physicist Peter Higgs has died aged 94. He proposed the particle that gives other particles mass – now named the Higgs boson and discovered by the Large Hadron Collider at CERN in 2012

The physicist Peter Higgs quietly revolutionised quantum field theory, then lived long enough to see the discovery of the Higgs boson he theorised. Despite receiving a Nobel prize, he remained in some ways as elusive as the particle that shares his name

From a photograph of algae choking an Indian river to a shocking depiction of the wearing away of the UK coast, these are some of the pictures in the running for the contest

Few volcanos come with more risk than Mexico's Popocatépetl, situated near Mexico City.  To mitigate danger, volcanologist Chiara Maria Petrone is trying to predict its next eruption

A 2200-year-old burial ground in northern Italy includes people interred with dogs and horses, perhaps showing they had strong bonds with their animals

Title: Low Levels of Brain Chemical May Control Appetite
Category: Health News
Created: 8/28/2008 2:00:00 AM
Last Editorial Review: 8/28/2008 12:00:00 AM

Title: Main Dishes May Fall Flat After Stellar Appetizers
Category: Health News
Created: 8/21/2015 12:00:00 AM
Last Editorial Review: 8/24/2015 12:00:00 AM

Title: Another Outbreak of Salmonella Traced to Pet Turtles
Category: Health News
Created: 8/30/2017 12:00:00 AM
Last Editorial Review: 8/31/2017 12:00:00 AM

Title: Dog Walking a Treat for Pet and Owner Alike
Category: Health News
Created: 9/1/2017 12:00:00 AM
Last Editorial Review: 9/1/2017 12:00:00 AM

Title: Hundreds of Human, Pet Homeopathy Products Recalled
Category: Health News
Created: 8/28/2018 12:00:00 AM
Last Editorial Review: 8/29/2018 12:00:00 AM

Title: AHA News: Obstacles Didn't Stop This Heart Defect Survivor From Competing on 'American Ninja Warrior
Category: Health News
Created: 8/12/2022 12:00:00 AM
Last Editorial Review: 8/15/2022 12:00:00 AM

Title: Pets Have Helped People With HIV Through Two Pandemics
Category: Health News
Created: 6/23/2022 12:00:00 AM
Last Editorial Review: 6/23/2022 12:00:00 AM

The aim of this study was to validate a previously developed deep learning model in 5 independent clinical trials. The predictive performance of this model was compared with the international prognostic index (IPI) and 2 models incorporating radiomic PET/CT features (clinical PET and PET models). Methods: In total, 1,132 diffuse large B-cell lymphoma patients were included: 296 for training and 836 for external validation. The primary outcome was 2-y time to progression. The deep learning model was trained on maximum-intensity projections from PET/CT scans. The clinical PET model included metabolic tumor volume, maximum distance from the bulkiest lesion to another lesion, SUV_peak, age, and performance status. The PET model included metabolic tumor volume, maximum distance from the bulkiest lesion to another lesion, and SUV_peak. Model performance was assessed using the area under the curve (AUC) and Kaplan–Meier curves. Results: The IPI yielded an AUC of 0.60 on all external data. The deep learning model yielded a significantly higher AUC of 0.66 (P < 0.01). For each individual clinical trial, the model was consistently better than IPI. Radiomic model AUCs remained higher for all clinical trials. The deep learning and clinical PET models showed equivalent performance (AUC, 0.69; P > 0.05). The PET model yielded the highest AUC of all models (AUC, 0.71; P < 0.05). Conclusion: The deep learning model predicted outcome in all trials with a higher performance than IPI and better survival curve separation. This model can predict treatment outcome in diffuse large B-cell lymphoma without tumor delineation but at the cost of a lower prognostic performance than with radiomics.

Recent studies have demonstrated promising results of fibroblast activation protein (FAP) inhibitor (FAPI) PET in prognosticating and monitoring interstitial lung diseases (ILDs). As a first step toward successful translation, our primary aim was to validate the FAPI PET uptake through immunohistochemistry in patients with advanced ILD who underwent lung transplantation after a FAPI PET scan. Methods: This is a preliminary analysis of a single-center, open-label, single-arm, prospective exploratory biodistribution study of ⁶⁸Ga-FAPI-46 PET imaging in patients with ILD (NCT05365802). Patients with ILD confirmed by high-resolution CT and scheduled for lung transplant were included. Tissue samples of explanted lungs were obtained from both the central and peripheral lung parenchyma of each lobe. Additional samples were obtained from areas of the lung corresponding to regions of FAPI PET activity. Immunohistochemical staining was performed with an anti-FAP antibody. Percentages of FAP immunohistochemistry-positive area were measured semiautomatically using QuPath software. SUVs in the areas of pathologic samples were measured on FAPI PET/CT by referencing the gross photomap of the explanted lung. A Spearman correlation coefficient test was used to assess the relationship between FAPI PET uptake and FAP immunohistochemical expression in each specimen. Results: Four patients with advanced ILD who underwent FAPI PET/CT before lung transplantation were included. The types of ILD were idiopathic pulmonary fibrosis (n = 2), rheumatoid arthritis–associated ILD (n = 1), and nonspecific interstitial pneumonia (n = 1). FAPI uptake was visualized mainly in the fibrotic area on CT. Twenty-nine surgical pathology samples from 3 patients were analyzed. FAP staining was predominantly positive in fibroblastic foci. FAPI PET SUV_max and SUV_mean showed a positive correlation with the immunohistochemical FAP expression score (SUV_max: r = 0.57, P = 0.001; SUV_mean: r = 0.54, P = 0.002). Conclusion: In this analysis conducted in patients who underwent lung transplantation after a FAPI PET scan, FAPI PET uptake was positively correlated with FAP immunohistochemistry. These findings provide a rationale for further investigation of FAPI PET as a potential imaging biomarker for ILD.

Simplified methods of acquisition and quantification would facilitate the use of synaptic density imaging in multicenter and longitudinal studies of Alzheimer disease (AD). We validated a simplified tissue-to-reference ratio method using SUV ratios (SUVRs) for estimating synaptic density with [¹¹C]UCB-J PET. Methods: Participants included 31 older adults with AD and 16 with normal cognition. The distribution volume ratio (DVR) using simplified reference tissue model 2 was compared with SUVR at short scan windows using a whole-cerebellum reference region. Results: Synaptic density was reduced in AD participants using DVR or SUVR. SUVR using later scan windows (60–90 or 70–90 min) was minimally biased, with the strongest correlation with DVR. Effect sizes using SUVR at these late time windows were minimally reduced compared with effect sizes with DVR. Conclusion: A simplified tissue-to-reference method may be useful for multicenter and longitudinal studies seeking to measure synaptic density in AD.

Chronic hypertension leads to injury and fibrosis in major organs. Fibroblast activation protein (FAP) is one of key molecules in tissue fibrosis, and ⁶⁸Ga-labeled FAP inhibitor-46 (FAPI46) PET is a recently developed method for evaluating FAP. The aim of this study was to evaluate FAP expression and fibrosis in a hypertension model and to test the feasibility of ⁶⁸Ga-FAPI46 PET in hypertension. Methods: Hypertension was induced in mice by angiotensin II infusion for 4 wk. ⁶⁸Ga-FAPI46 biodistribution studies and PET scanning were conducted at 1, 2, and 4 wk after hypertension modeling, and uptake in the major organs was measured. The FAP expression and fibrosis formation of the heart and kidney tissues were analyzed and compared with ⁶⁸Ga-FAPI46 uptake. Subgroups of the hypertension model underwent angiotensin receptor blocker administration and high-dose FAPI46 blocking, for comparison. As a preliminary human study, ⁶⁸Ga-FAPI46 PET images of lung cancer patients were analyzed and compared between hypertension and control groups. Results: Uptake of ⁶⁸Ga-FAPI46 in the heart and kidneys was significantly higher in the hypertension group than in the sham group as early as week 1 and decreased after week 2. The uptake was specifically blocked in the high-dose blocking study. Immunohistochemistry also revealed FAP expression in both heart and kidney tissues. However, overt fibrosis was observed in the heart, whereas it was absent from the kidneys. The angiotensin receptor blocker–treated group showed lower uptake in the heart and kidneys than did the hypertension group. In the pilot human study, renal uptake of ⁶⁸Ga-FAPI46 significantly differed between the hypertension and control groups. Conclusion: In hypertension, FAP expression is increased in the heart and kidneys from the early phases and decreases over time. FAP expression appears to represent fibrosis activity preceding or underlying fibrotic tissue formation. ⁶⁸Ga-FAPI46 PET has potential as an effective imaging method for evaluating FAP expression in progressive fibrosis by hypertension.

The role of somatostatin receptor (SSTR) PET/CT, using ⁶⁸Ga-based tracers or [⁶⁴Cu]Cu-DOTATATE (⁶⁴Cu-DOTATATE), in the management of patients with neuroendocrine neoplasm (NEN) is guided by appropriate use criteria (AUC). In this study, we performed systematic analyses of referral patterns and image findings of routine ⁶⁴Cu-DOTATATE PET/CT scans to support AUC development. Methods: We included all clinical routine ⁶⁴Cu-DOTATATE PET/CT scans performed between April 10, 2018 (start of clinical use), and May 2, 2022, at Copenhagen University Hospital–Rigshospitalet. We reviewed the referral text and image report of each scan and classified the indication according to clinical scenarios as listed in the AUC. Results: In total, 1,290 patients underwent 2,249 ⁶⁴Cu-DOTATATE PET/CT scans. Monitoring of patients with NEN seen both on conventional imaging and on SSTR PET without clinical evidence of progression was the most common indication (defined as "may be appropriate" in the AUC) and accounted for 703 (31.3%) scans. Initial staging after NEN diagnosis ("appropriate" in the AUC) and restaging after curative-intent surgery ("may be appropriate" in the AUC) accounted for 221 (9.8%) and 241 (10.7%) scans, respectively. Selection of patients eligible for peptide receptor radionuclide therapy ("appropriate" in the AUC) and restaging after peptide receptor radionuclide therapy completion ("appropriate" in the AUC) accounted for 95 (4.2%) and 115 (5.1%) scans, respectively. The number of scans performed for indications not defined in the AUC was 371 (16.5%). Image result analysis revealed no disease in 669 scans (29.7%), stable disease in 582 (25.9%), and progression in 461 (20.5%). In 99 of the 461 (21.5%) scans, progression was detected on PET but not on CT. Conclusion: Our study provided real-life data that may contribute to support development of ⁶⁴Cu-DOTATATE/SSTR PET/CT guidelines including AUC. Some scenarios listed as "may be appropriate" in the current AUC were frequent in our data. Monitoring of patients with NEN without clinical evidence of progression was the most frequent indication for ⁶⁴Cu-DOTATATE PET/CT, in which disease progression was detected in more than one third, and a large proportion was visible by PET only. We therefore conclude that this scenario could potentially be classified as appropriate.

Neuroendocrine tumor (NET) metastases to the heart are found in 1%–4% of NET patients and have been reported primarily in the form of individual cases. We investigated the prevalence, clinical characteristics, imaging features, and outcomes of NET patients with cardiac metastases on ⁶⁸Ga-DOTATATE PET/CT. Methods: ⁶⁸Ga-DOTATATE PET/CT of 490 consecutive patients from a single institution were retrospectively reviewed for sites of metastases. The cumulative cardiovascular event rate and overall survival of patients with cardiac NET metastases (CNMs) were compared with those of a control group of metastatic NET patients without cardiac metastases. In patients with CNMs, the cardiac SUV_max with and without normalization to the myocardial background uptake was compared with a separate cohort of 11 patients with active cardiac sarcoidosis who underwent ⁶⁸Ga-DOTATATE PET/CT for research purposes. Results: In total, 270 patients with metastatic NETs were identified, 9 (3.3%) of whom had CNMs. All 9 patients had grade 1–2 gastroenteropancreatic NETs, most commonly from the small intestine (7 patients). The control group consisted of 140 patients with metastatic grade 1–2 gastroenteropancreatic NETs. On Kaplan–Meier analysis, there was no significant difference in the risk of cardiovascular adverse events (P = 0.91 on log-rank test) or mortality (P = 0.83) between the metastatic NET patients with and without cardiac metastases. The degree of cardiac DOTATATE uptake was significantly higher in CNMs than in patients with cardiac sarcoidosis without overlap, in terms of both cardiac SUV_max (P = 0.027) and SUV_max–to–myocardial background ratio (P = 0.021). Conclusion: Routine ⁶⁸Ga-DOTATATE PET/CT can be used to identify CNMs in 3% of patients with metastatic NETs. CNMs do not confer added cardiovascular or mortality risk. A distinguishing feature of CNMs is their high degree of DOTATATE uptake compared with focal myocardial inflammation.

In Canada and across the globe, access to PSMA PET/CT is limited and expensive. For patients with biochemical recurrence (BCR) after treatment for prostate cancer, novel strategies are needed to better stratify patients who may or may not benefit from a PSMA PET scan. The role of the free-to-total prostate-specific antigen (PSA) ratio (FPSAR) in posttreatment prostate cancer, specifically in the PSMA PET/CT era, remains unknown. Our aim in this study was to determine the association of FPSAR in patients referred for ¹⁸F-DCFPyL PSMA PET/CT in the BCR setting and assess the correlation between FPSAR and ¹⁸F-DCFPyL PSMA PET/CT positivity (local recurrence or distant metastases). Methods: This prospective study included 137 patients who were referred for ¹⁸F-DCFPyL PSMA PET/CT and had BCR with a total PSA of less than 1 ng/mL after radical prostatectomy (RP) (including adjuvant or salvage radiotherapy). Blood samples were collected on the day of ¹⁸F-DCFPyL PSMA PET/CT. FPSAR was categorized as less than 0.10 or as 0.10 or more. A positive ¹⁸F-DCFPyL PSMA PET/CT scan was defined by a PROMISE classification lesion score of 2 or 3, irrespective of the site of increased tracer uptake (e.g., prostate, pelvic nodes, bone, or viscera). Results: Overall, 137 blood samples of patients with BCR after RP were analyzed to calculate FPSAR. The median age at ¹⁸F-DCFPyL PSMA PET/CT was 68.6 y (interquartile range, 63.0–72.4 y), and the median PSA at ¹⁸F-DCFPyL PSMA PET/CT was 0.3 ng/mL (interquartile range, 0.3–0.6 ng/mL). Eighty-six patients (62.8%) had an FPSAR of less than 0.10, whereas 51 patients (37.2%) had an FPSAR of 0.10 or more. An FPSAR of 0.10 or more was identified as an independent predictor of a positive ¹⁸F-DCFPyL PSMA PET/CT scan, with an odds ratio of 6.99 (95% CI, 2.96–16.51; P < 0.001). Conclusion: An FPSAR of 0.10 or more after RP independently correlated with increased odds of a positive ¹⁸F-DCFPyL PSMA PET/CT scan among BCR post-RP patients. These findings may offer an inexpensive method by which to triage access to ¹⁸F-DCFPyL PSMA PET/CT in jurisdictions where availability is not replete.

Identifying cancer therapy resistance is a key time-saving tool for physicians. Part of chemotherapy resistance includes senescence, a persistent state without cell division or cell death. Chemically inducing senescence with the combination of trametinib and palbociclib (TP) yields several tumorigenic and prometastatic factors in pancreatic cancer models with many potential antibody-based targets. In particular, urokinase plasminogen activator receptor (uPAR) has been shown to be a membrane-bound marker of senescence in addition to an oncology target. Methods: Here, 2 antibodies against murine uPAR and human uPAR were developed as immuno-PET agents to noninvasively track uPAR antigen abundance. Results: TP treatment increased cell uptake both in murine KPC cells and in human MiaPaCa2 cells. In vivo, subcutaneously implanted murine KPC tumors had high tumor uptake with the antimurine uPAR antibody independently of TP in young mice, yet uPAR uptake was maintained in aged mice on TP. Mice xenografted with human MiaPaCa2 tumors showed a significant increase in tumor uptake on TP therapy when imaged with the antihuman uPAR antibody. Imaging with either uPAR antibody was found to be more tumor-selective than imaging with [¹⁸F]FDG or [¹⁸F]F-DPA-714. Conclusion: The use of radiolabeled uPAR-targeting antibodies provides a new antibody-based PET imaging candidate for pancreatic cancer imaging as well as chemotherapy-induced senescence.

Intrapatient intermetastatic heterogeneity (IIH) has been demonstrated in metastatic castration-resistant prostate cancer (mCRPC) patients and is of the utmost importance for radiopharmaceutical therapy (RPT) eligibility. This study was designed to determine the prevalence of IIH and RPT eligibility in mCRPC patients through a triple-tracer PET imaging strategy. Methods: This was a multisite prospective observational study in which mCRPC patients underwent both ¹⁸F-FDG and ⁶⁸Ga-prostate-specific membrane antigen (PSMA)–617 PET/CT scans. A third scan with ⁶⁸Ga-DOTATATE, a potential biomarker of neuroendocrine differentiation, was performed if an ¹⁸F-FDG–positive/⁶⁸Ga-PSMA–negative lesion was found. Per-tracer lesion positivity was defined as having an uptake at least 50% above that of the liver. IIH prevalence was defined as the percentage of participants having at least 2 lesions with discordant features on multitracer PET. Results: IIH was observed in 81 patients (82.7%), and at least 1 ¹⁸F-FDG–positive/⁶⁸Ga-PSMA–negative lesion was found in 45 patients (45.9%). Of the 37 participants who also underwent ⁶⁸Ga-DOTATATE PET/CT, 6 (16.2%) had at least 1 ⁶⁸Ga-DOTATATE–positive lesion. In total, 12 different combinations of lesion imaging phenotypes were observed. On the basis of our prespecified criteria, 52 (53.1%) participants were determined to be eligible for PSMA RPT, but none for DOTATATE RPT. Patients with IIH had a significantly shorter median overall survival than patients without IIH (9.5 mo vs. not reached; log-rank P = 0.03; hazard ratio, 2.7; 95% CI, 1.1–6.8). Conclusion: Most mCRPC patients showed IIH, which was associated with shorter overall survival. On the basis of a triple-tracer PET approach, multiple phenotypic combinations were found. Correlation of these imaging phenotypes with genomics and treatment response will be relevant for precision medicine.

This single-center, single-arm, phase II trial (ChiCTR2100050057) investigated the ability of ¹⁸F-labeled fibroblast activation protein inhibitor ([¹⁸F]AlF-NOTA-FAPI-04, denoted as ¹⁸F-FAPI) PET/CT to predict the response to neoadjuvant camrelizumab plus chemotherapy (nCC) in locally advanced esophageal squamous cell carcinoma (LA-ESCC). Methods: This study included 32 newly diagnosed LA-ESCC participants who underwent ¹⁸F-FAPI PET/CT at baseline, of whom 23 also underwent scanning after 2 cycles of nCC. The participants underwent surgery after 2 cycles of nCC. Recorded PET parameters included maximum, peak, and mean SUVs and tumor-to-background ratios (TBRs), metabolic tumor volume, and total lesion FAP expression. PET parameters were compared between patient groups with good and poor pathologic responses, and the predictive performance for treatment response was analyzed. Results: The good and poor response groups each included 16 participants (16/32, 50.0%). On ¹⁸F-FAPI PET/CT, the posttreatment SUVs were significantly lower in good responders than in poor responders, whereas the changes in SUVs with treatment were significantly higher (all P < 0.05). SUV_max (area under the curve [AUC], 0.87; P = 0.0026), SUV_peak (AUC, 0.89; P = 0.0017), SUV_mean (AUC, 0.88; P = 0.0021), TBR_max (AUC, 0.86; P = 0.0031), and TBR_mean (AUC, 0.88; P = 0.0021) after nCC were significant predictors of pathologic response to nCC, with sensitivities of 63.64%–81.82% and specificities of 83.33%–100%. Changes in SUV_max (AUC, 0.81; P = 0.0116), SUV_peak (AUC, 0.82; P = 0.0097), SUV_mean (AUC, 0.81; P = 0.0116), and TBR_mean (AUC, 0.74; P = 0.0489) also were significant predictors of the pathologic response to nCC, with sensitivities and specificities in similar ranges. Conclusion: ¹⁸F-FAPI PET/CT parameters after treatment and their changes from baseline can predict the pathologic response to nCC in LA-ESCC participants.

In several malignancies, only a limited number of patients respond to immune checkpoint inhibitors. Predicting and monitoring responses to these inhibitors represent an unmet clinical need. Here, we developed a PET/CT probe targeting granzyme B, [⁶⁸Ga]Ga-NOTA-Gly-Gly-Gly-Ile-Glu-Pro-Asp-CHO (GSI), and aimed to investigate whether it can be used to monitor the effects of immune checkpoint inhibitors early in the course of therapy. Methods: Seventy-two patients with gastric cancer (stages III–IV) were recruited for [⁶⁸Ga]Ga-NOTA-GSI PET/CT imaging after 2 or 3 cycles of the immunotherapy, and 40 patients were included in the final analysis. The SUV_max of primary tumors (SUV_max-t), SUV_max of metastatic lymph nodes (SUV_max-LN), and SUV_max of normal tissues (liver and blood pool) were measured, and their target-to-liver background ratio (TLR) and target-to-blood background ratio (TBR) were denoted for primary tumors as TLR_tumor and TBR_tumor and for metastatic lymph nodes as TLR_LN and TBR_LN, respectively. The treatment responses were assessed within 1 wk after full-course treatment according to RECIST version 1.1. Wilcoxon rank-sum tests were used to compare the PET/CT parameters between responders and nonresponders. Receiver operating characteristic curve analysis was used to assess the diagnostic efficacy of [⁶⁸Ga]Ga-NOTA-GSI PET/CT parameters in identifying responders. Two-tailed P value of less than 0.05 was considered statistically significant. Results: We found that SUV_max-t, TLR_tumor, TBR_tumor, SUV_max-LN, and TBR_LN were higher in responders than in nonresponders (2.49 ± 0.58 vs. 1.55 ± 0.48, P = 0.000; 2.24 ± 0.48 vs. 1.74 ± 0.67, P = 0.007; 1.38 ± 0.43 vs. 0.90 ± 0.23, P = 0.000; 2.24 ± 0.99 vs. 1.42 ± 0.55, P = 0.003; and 1.28 ± 0.68 vs. 0.83 ± 0.32, P = 0.012, respectively). According to receiver operating characteristic curve analysis, the area under the curve for SUV_max-t, TBR_tumor, TLR_tumor, SUV_max-LN, TLR_LN, and TBR_LN was 0.886, 0.866, 0.746, 0.772, 0.648, and 0.731, respectively. The threshold of SUV_max-t was 2.05, and its sensitivity and specificity were 81.0% and 84.2%, respectively. In addition, multivariate logistic regression indicated that TBR_tumor was an independent predictor of treatment response (P = 0.03). Conclusion: Our results indicated that [⁶⁸Ga]Ga-NOTA-GSI PET/CT is a promising tool for predicting early response to combined immunotherapy in gastric cancer patients.

The clinical impact of 16α-¹⁸F-fluoro-17β-estradiol (¹⁸F-FES) PET/CT on patient management has not been well investigated. The aim of this study was to assess the clinical impact of ¹⁸F-FES PET/CT on the management of patients with recurrent or metastatic breast cancer. Methods: Study subjects were identified retrospectively from a database of a prospective trial for postmarketing surveillance of ¹⁸F-FES between 2021 and 2023. Patients who were suspected or known to have recurrent or metastatic estrogen receptor–positive breast cancer based on a routine standard workup were included. Planned management before and actual management after ¹⁸F-FES PET/CT were assessed by 2 experienced medical oncologists via medical chart review. A 5-point questionnaire was provided to evaluate the value of ¹⁸F-FES PET/CT for management planning. The rate of intention-to-treat and interdisciplinary changes, and the impact of ¹⁸F-FES PET/CT according to PET/CT result or clinical indication, were examined. Results: Of the 344 included patients, 120 (35%) experienced a change in management after ¹⁸F-FES PET/CT. In 139 (40%) patients,¹⁸F-FES PET/CT supported the existing management decision without a change in management. Intention-to-treat and interdisciplinary changes accounted for 64% (77/120) and 68% (82/120) of all changes, respectively. A higher rate of change was observed when lesions were ¹⁸F-FES–negative (44% [36/81]) than ¹⁸F-FES–positive (30% [51/172]) or mixed ¹⁸F-FES–positive/negative (36% [33/91]). Regarding clinical indications, the highest rate of change was shown when evaluating the origins of metastasis of double primary cancers (64% [9/14]). Conclusion: ¹⁸F-FES PET/CT modified the management of recurrent or metastatic breast cancer, serving as an impactful imaging modality in clinical practice.

Enshrouded has received what developers Keen Games are calling the survival game's "most sizable" update yet, sizable being an appropriate word for mountains. Expect a new playable area, the Alabaneve Summits, with its own enemies, resources, non-threatening wildlife and quests. The maximum character level has risen to 35! There are new townsfolk to find and place in your poorly built houses! You can tame animals, and make them live in poorly built houses too! You can get hypothermia!

Read more

Back in the misty reaches of time (March) popular farming sim Stardew Valley got a big update that added more pets to the game (it also let you drink mayonaise but let's not get sidetracked). Those new cats, dogs, and turtles had the cute distinction of being able to wear hats, should you choose to kit your wee friends out. Now, following many months of smaller updates to the game, it seems those hats are causing a problem. "[If] you are experiencing performance issues in Stardew Valley 1.6, remove all hats from pets," said creator Eric Barone in a xeet. When asked the lore-accurate cause of this problem, he blamed: "a strange rash".

Read more

Putting aside my natural annoyance at Metal Gear Solid Delta: Snake Eater for almost beating out the Twarhammer series in the headline real estate wars, I am more than a little excited to play. Some days, you simply must feast on a tree frog, and while we still don’t have a solid release date, that day doesn’t feel too far away. Good news for stealth fans, and perhaps gooder news for a dozen strapline writers sweating profusely, soiling themselves in anticipation of using “kept you waiting, huh?”.

Until then, I at least have a steady drip feed of new information to keep me sated, the latest of which is the substantial hint that there'll be some new dialogue in the game, as per the video below. Alongside that, the previously pseudonymous Suzetta Miñet - who was credited with voicing EVA in MGS3 and Peace Walker - has revealed herself to be Jodi Benson, the voice of Ariel in Disney’s The Little Mermaid. Cheers for the spot, Automaton West.

Read more

In a basement beneath City St George's, University of London, senior NATO leaders watch on as four research teams demonstrate the latest in AI-controlled, autonomous drone technolo0gy

Our Future Chronicles column explores an imagined history of inventions and developments yet to come. We visit 2032 and meet artificial animals that love their owners, without the carbon footprint of biological pets. Rowan Hooper explains how it happened

This is a sponsored article brought to you by Khalifa University of Science and Technology.

A total of eight intense competitions to inspire creativity and innovation along with 13 forums dedicated to diverse segments of robotics and artificial intelligence will be part of the 36th edition of the IEEE/RSJ International Conference on Intelligent Robots and Systems (IROS 2024) in Abu Dhabi.

These competitions at the Middle East and North Africa (MENA) region’s first-ever global conference and exhibition from 14-18 October 2024 at the Abu Dhabi National Exhibition Center (ADNEC) will highlight some of the key aspects of robotics. These include physical or athletic intelligence of robots, remote robot navigation, robot manipulation, underwater robotics, perception and sensing as well as challenges for wildlife preservation.

This edition of IROS is one of the largest of its kind globally in this category because of active participation across all levels, with 5,740 authors, 16 keynote speakers, 46 workshops, 11 tutorials, as well as 28 exhibitors and 12 startups. The forums at IROS will explore the rapidly evolving role of robotics in many industry sectors as well as policy-making and regulatory areas. Several leading corporate majors, and industry professionals from across the globe are gathering for IROS 2024 which is themed “Robotics for Sustainable Development.”

“The intense robotics competitions will inspire creativity, while the products on display as well as keynotes will pave the way for more community-relevant solutions.” —Jorge Dias, IROS 2024 General Chair

Dr. Jorge Dias, IROS 2024 General Chair, said: “Such a large gathering of scientists, researchers, industry leaders and government stakeholders in Abu Dhabi for IROS 2024 also demonstrates the role of UAE in pioneering new technologies and in providing an international platform for knowledge exchange and sharing of expertise. The intense robotics competitions will inspire creativity, while the products on display as well as keynotes will pave the way for more community-relevant solutions.”

The competitions are:

• 2nd AI Olympics With RealAIGym: Is AI Ready for Athletic Intelligence in the Real World? focusing on the physical or athletic intelligence of robots

• The Earth Rovers Challenge on remote robot navigation

• Robotic Construction Challenge and the euROBIN Manipulation Skill Versatility Challenge (MSVC) on robot manipulation

• Underwater Robotics Challenges on innovation and problem-solving in underwater robotics and artificial intelligence

• ROAD-IROS: Automatic Data Annotation Challenge for ROAD Dataset on perception and sensing

• 21st F1Tenth Autonomous Racing Competition

• IEEE RAS Quadruped Robot Challenge (QRC), focusing on navigation

In addition to these competitions, the Falcon Monitoring Challenge (FMC) will focus on advancing the field of wildlife tracking and conservation through the development of sophisticated, noninvasive monitoring systems.

Khalifa University

IROS 2024 will also include three keynote talks on ‘Robotic Competitions’ that will be moderated by Professor Lakmal Seneviratne, Director, Center for Autonomous Robotic Systems (KU-CARS), Khalifa University. The keynotes will be delivered by Professor Pedro Lima, Institute for Systems and Robotics, Instituto Superior Técnico, University of. Lisbon, Portugal; Dr. Timothy Chung, General Manager, Autonomy and Robotics, Microsoft, US; and Dr. Ubbo Visser, President of the RoboCup Federation, Director of Graduate Studies, and Associate Professor of Computer Science, University of Miami, US.

The forums at IROS 2024 will include:

• Robotics in Africa Forum

• Marine Robotics in Ocean Decade Initiative for Sustainable Development

• Robots for Sustainability and Sustainable Robots

• Government Forum: Funding for Robotics Research, Human-Avatars Symbiosis: Can you imagine a future society where you can remotely control multiple avatars?

• Moonshot R&D Program Goal 3 Forum. Envisioning a Future of Human-Robot Co-living: Potential for Robotics to Transform Human Lives

Other forums include:

• Sustainable Medical and Surgical Robotics

• Empowering Diverse Voices in Robotics, Robotics & AI in the UAE: Research Innovation and Entrepreneurship

• Europe Regulates Artificial Intelligence: the Challenge for Robotics, Industrial Opportunities and Socio-Economic Impact of Medical Robotics

• The Future of Work: AI-Enhanced Robotics and Human Interaction Research in M3S

• Robots for a Better Tomorrow: Wellbeing Through Advanced Technology.

One of the largest and most important robotics research conferences in the world, IROS 2024 provides a platform for the international robotics community to exchange knowledge and ideas about the latest advances in intelligent robots and smart machines. A total of 3,344 paper submissions representing 60 countries, have been received from researchers and scientists across the world. China tops the list with more than 1,000 papers, the US with 777, Germany with 302, Japan with 253, and the UK and South Korea with 173 each. The UAE remains top in the Arab region with 68 papers.

One of the largest and most important robotics research conferences in the world, IROS 2024 provides a platform for the international robotics community to exchange knowledge and ideas.

For eight consecutive years since 2017, Abu Dhabi has remained first on the world’s safest cities list, according to online database Numbeo, which assessed 329 global cities for the 2024 listing. This reflects the emirate’s ongoing efforts to ensure a good quality of life for citizens and residents. With a multicultural community, Abu Dhabi is home to people from more than 200 nationalities, and draws a large number of tourists to some of the top art galleries in the city such as Louvre Abu Dhabi and the Guggenheim Abu Dhabi, as well as other destinations such as Ferrari World Abu Dhabi and Warner Bros. World™ Abu Dhabi.

Because of its listing as one of the safest cities, Abu Dhabi continues to host several international conferences and exhibitions. Abu Dhabi is set to host the UNCTAD World Investment Forum, the 13th World Trade Organization (WTO) Ministerial Conference (MC13), the 12th World Environment Education Congress in 2024, and the IUCN World Conservation Congress in 2025.

IROS 2024 is sponsored by IEEE Robotics and Automation Society, Abu Dhabi Convention and Exhibition Bureau, the Robotics Society of Japan (RSJ), the Society of Instrument and Control Engineers (SICE), the New Technology Foundation, and the IEEE Industrial Electronics Society (IES).

More information at https://iros2024-abudhabi.org/

President-elect Donald Trump said he will nominate Fox News host Pete Hegseth to be secretary of defense.

In order to promote the flow of soothing energies, starting October 1st all TIGS folk are wholly encouraged to consider taking part in The Wholesome Competition. Less of a bloody-toothed competition between gladiatorial rivals and more of a friendly environment to tinker away merrily on a small project with pals. A call to jolly cooperation, […]

The Competition Bureau has announced that it has expanded its investigation into Google’s online ad practices. This is the first major update to the investigation since it began in 2020, and a year later the competition watchdog obtained a court order from the Federal Courts of Appeal, requiring Google to produce records and written information […]

In Canada, your IP address has the right to remain silent. Elon Musk is suing OpenAI for not being Open. Apple faces a class action not allowing competitive access to backup services and the World Server Throwing Competition in March 2024 is accused of being too violent towards servers.   All this and more on the […]

Former Fox News host Pete Hegseth has been selected by President-elect Trump to serve as his secretary of defense. Hegseth served in the U.S. Army.

While other bears battled over fish in a prime spot, Otis would sit off to the side and wait for the fish to come to him. But so far this year, he hasn’t been spotted in Katmai National Park and Preserve

On Tuesday’s broadcast of MSNBC’s “Morning Joe,” Rep. Ritchie Torres (D-NY) stated that “the Biden administration demonstrated incompetence in managing the migrant crisis,” President Joe Biden “had the unilateral ability to issue an executive order restricting migration at the border, and he waited two-and-a-half years,” because the order “was unpopular among far-left elites who have outsized power over the policymaking and messaging of the Democratic Party.” Torres said, “[O]n the subject of immigration, there was genuine political malpractice. Since 2022, there has been an unprecedented wave of migration, whose impact was felt, not only at the border, but in cities like New York, where the shelter system and our municipal finances were completely overwhelmed. … Despite clear signs of popular discontent, it took the Biden administration two-and-a-half years to issue an executive order restricting migration at the border, and by then it was too late. The Republicans had won the issue, had weaponized it against us. And when the President issued the executive order, polling revealed that it was popular among the American people, among people from every racial category, blacks and whites, Latinos and Asians. So, if it was effective at reducing migration at the border and if it was

The post Dem Rep. Torres: Biden Showed ‘Incompetence’ on Immigration Because He Catered to ‘Far-Left Elites’ appeared first on Breitbart.

President-elect Donald Trump nominated Fox News host Pete Hegseth to serve as his Secretary of Defense, hailing him as a champion of his "peace through strength" policy.

The post Trump Nominates Fox News Host Pete Hegseth for Secretary of Defense: ‘Nobody Fights Harder for the Troops’ appeared first on Breitbart.

The inaugural Red Lorry Film Festival in 2024 saw over 100 international films across various categories and languages